NYSE · GSK
GSK plc
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarThe next earnings date for GSK has not been announced yet.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Dec 2026 | $0.77 | $0.88 | $0.73 | 5 |
| Mar 2027 | $1.27 | $1.30 | $1.25 | 2 |
| Jun 2027 | $1.35 | $1.38 | $1.32 | 2 |
| Sep 2027 | $1.54 | $1.60 | $1.48 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · The Motley Fool · MarketBeat- Zacks · Oct 29, 11:23 AM EDTGSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?GSK's Specialty Medicines growth, deep pipeline and dividend offer a compelling case against MRNA's oncology potential and premium valuation.
- RTTNews · Oct 29, 4:01 AM EDTBiotech Stocks Facing FDA Decision In November 2026(RTTNews) – The FDA's November calendar has more than a dozen PDUFA dates on the horizon, setting the stage for an eventful month in the regulatory landscape.
- The Motley Fool · Oct 28, 5:58 PM EDTGSK (GSK) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Oct 28, 2:04 PM EDTWhat GSK (GSK) Said on Its Q3 Earnings CallMarketBeat Week in Review – 06/08 – 06/12GSK (NYSE:GSK) reported third-quarter sales growth of 5% at constant exchange rates to £8.9 billion, supported by specialty medicines, new product launches and oncology growth. Core operating profit increased 5%, while core earnings per sh
- Zacks · Oct 28, 10:45 AM EDTGSK Q3 Earnings Top Mark, Stock Down on Soft Vaccines SalesGSK's Q3 earnings beat estimates as HIV, oncology and respiratory medicines drive revenue growth, while declining vaccine sales weigh on shares.
- Zacks · Oct 28, 6:10 AM EDTGSK (GSK) Q3 Earnings and Revenues Beat EstimatesGlaxo (GSK) delivered earnings and revenue surprises of +5.00% and +1.24%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Oct 28, 3:41 AM EDTGSK Q3 Core Operating Profit Rises; Reaffirms 2026 Guidance(RTTNews) – GSK (GSK, GSK.L, GS71.DE) reported third-quarter profit before tax of 1.935 billion pounds, compared with 2.456 billion pounds in the prior year. Earnings per share declined to 38.5 pence from 49.9 pence, a year ago. Core operating profit reached 3.076 billion pounds,
- MarketBeat · Oct 27, 2:04 PM EDTGSK Showcases Strong Oncology Pipeline Data at ESMO Investor UpdateMarketBeat Week in Review – 06/08 – 06/12GSK (NYSE:GSK) highlighted clinical data across its oncology pipeline at the European Society for Medical Oncology meeting, including updates for its B7-H3 antibody-drug conjugate ris-rez, B7-H4 ADC mo-rez, PD-1 therapy dostarlimab and ROS
- Zacks · Oct 27, 10:50 AM EDTGilead to Report Q3 Earnings: How Should You Play the Stock Now?Gilead Sciences heads into Q3 earnings with strong HIV sales, Yeztugo momentum and expanding oncology prospects, but competitive pressures warrant caution.
- RTTNews · Oct 22, 11:31 AM EDTGavi, UNICEF Cut GSK Mosquirix Vaccine Price By 40%(RTTNews) – Gavi and UNICEF have reached an agreement to reduce the price of the RTS,S/AS01 malaria vaccine, marketed as Mosquirix, by about 40%, a move expected to save approximately $50 million between 2027 and 2029.
- Zacks · Oct 22, 9:00 AM EDTAlnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 21, 10:00 AM EDTCan Expanding Ivonescimab Development Unlock SMMT's Growth Potential?Summit is expanding ivonescimab beyond lung cancer into colorectal, bladder, kidney and other cancers, backed by promising early data and collaboration deals.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for GSK plc from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.